Grössmann, N. (2020): Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Update July 2020. Oncology Fact Sheet Nr. 7.

Grössmann, N. (2021): Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen. Update February 2021. Oncology Fact Sheet Nr. 8.

Grössmann, N. (2020): Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma. Update July 2020. Oncology Fact Sheet Nr. 9.

Grössmann, N. (2020): Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML). Update July 2020. Oncology Fact Sheet Nr. 10.

Grössmann, N. (2021): Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. Update February 2021. Oncology Fact Sheet Nr. 12.

Grössmann, N. (2020): Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer. Update July 2020. Oncology Fact Sheet Nr. 11.

Grössmann, N. (2021): Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC. Update February 2021. Oncology Fact Sheet Nr. 13.

Grössmann, N. and Wild, C. (2020): Update PET/PET-CT evidence for need based planning in the area of oncology. AIHTA Policy Brief 003.

Wolf, S. and Grössmann, N. (2020): Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble). Decision Support Document 123.

Grössmann, N. (2020): Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL). Oncology Fact Sheet Nr. 14.

Grössmann, N. (2021): Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL). Update February 2021. Oncology Fact Sheet Nr. 15.

Rothschedl, E. and Wolf, S. and Grössmann, N. (2021): Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST). Update September 2022. Oncology Fact Sheet Nr. 16.

Rothschedl, E. and Grössmann, N. (2020): Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM). Update February 2024. Oncology Fact Sheet Nr. 17.

Grössmann, N. (2021): Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Update February 2021. Oncology Fact Sheet Nr. 18.

Grössmann, N. (2021): Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Update February 2021. Oncology Fact Sheet Nr. 19.

Grössmann, N. (2021): Duvelisib (Copiktra®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL). Update August 2021. Oncology Fact Sheet Nr. 44.

Wild, C. and Wohlhöfner, K. and Sehic, O. and Grössmann, N. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: ATMPs and Gene Therapies. AIHTA Policy Brief 006b.

Grössmann, N. (2021): Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC). Update February 2021. Oncology Fact Sheet Nr. 20.

Grössmann, N. (2021): Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC). Update February 2021. Oncology Fact Sheet Nr. 21.

Grössmann, N. (2021): Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer. Update February 2021. Oncology Fact Sheet Nr. 22.

Grössmann, N. (2021): Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC). Update February 2021. Oncology Fact Sheet Nr. 23.

Grössmann, N. (2021): Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer. Update February 2021. Oncology Fact Sheet Nr. 24.

Wolf, S. and Grössmann, N. (2020): Home-Treatment in Child and Adolescent Psychiatry: An Analysis of the Effectiveness and Possible Implementation in Austria. HTA-Projektbericht 129.

Grössmann, N. (2021): Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL). Update February 2021. Oncology Fact Sheet Nr. 25.

Grössmann, N. (2021): Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC). Update February 2021. Oncology Fact Sheet Nr. 26.

Grössmann, N. (2020): Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL). Update February 2021. Oncology Fact Sheet Nr. 27.

Grössmann, N. (2021): Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM). Update February 2021. Oncology Fact Sheet Nr. 29.

Grössmann, N. (2021): A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer. Update February 2021. Oncology Fact Sheet Nr. 30.

Grössmann, N. (2020): Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma. Update February 2021. Oncology Fact Sheet Nr. 31.

Grössmann, N. (2021): Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer. Update March 2021. Oncology Fact Sheet Nr. 32.

Grössmann, N. (2021): Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis. Update April 2021. Oncology Fact Sheet Nr. 33.

Grössmann, N. (2021): Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI-H or dMMR colorectal cancer. Update April 2021. Oncology Fact Sheet Nr. 34.

Grössmann, N. (2021): Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer. Update May 2021. Oncology Fact Sheet Nr. 36.

Grössmann, N. (2021): Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer. Update April 2021. Oncology Fact Sheet Nr. 37.

Grössmann, N. (2021): Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement. Update May 2021. Oncology Fact Sheet Nr. 40.

Grössmann, N. (2021): Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Update August 2021. Oncology Fact Sheet Nr. 42.

Grössmann, N. (2021): Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM). Update August 2021. Oncology Fact Sheet Nr. 43.

Grössmann, N. (2021): Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). Update August 2021. Oncology Fact Sheet Nr. 45.

Grössmann, N. (2021): Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). Update August 2021. Oncology Fact Sheet Nr. 46.

Grössmann, N. and Wolf, S. and Wild, C. (2021): Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD). Decision Support Document 127.

Rothschedl, E. and Wolf, S. and Grössmann, N. (2021): Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL). Withdrawal of the marketing authorisation in the European Union. Update November 2022. Oncology Fact Sheet Nr. 35.

Rothschedl, E. and Grössmann, N. (2023): Pirtobrutinib (JaypircaTM) as monotherapy for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL). Update December 2023. Fact Sheet Nr. 131.

Rothschedl, E. and Grössmann, N. (2023): Ivosidenib (Tibsovo®) monotherapy for the treatment of locally advanced or metastatic cholangiocarcinoma. Update February 2024. Fact Sheet Nr. 127.

Rothschedl, E. and Grössmann, N. (2023): Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL). Update February 2024. Fact Sheet Nr. 130.

Rothschedl, E. and Grössmann, N. (2023): Tremelimumab (Imjudo®) with durvalumab (Imfinzi®) and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC). Update October 2023. Fact Sheet Nr. 135.

Rothschedl, E. and Grössmann, N. (2023): Trifluridine/tipiracil (Lonsurf®, TAS-02) with bevacizumab for the treatment of metastatic colorectal cancer (CRC). Update October 2023. Fact Sheet Nr. 136.

Rothschedl, E. and Grössmann, N. (2023): Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer. Update October 2023. Fact Sheet Nr. 137.

Rothschedl, E. and Grössmann, N. (2023): Crisantaspase (Enrylaze®) for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). Update June 2024. Fact Sheet Nr. 138.

Rothschedl, E. and Grössmann, N. (2023): Cedazuridine/decitabine (Inaqovi®) for the treatment of newly diagnosed acute myeloid leukaemia (AML). Update December 2023. Fact Sheet Nr. 139.

Rothschedl, E. and Grössmann, N. (2023): Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer. Update December 2023. Fact Sheet Nr. 140.

Rothschedl, E. and Grössmann, N. (2023): Talquetamab (Talvey®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM). Update December 2023. Fact Sheet Nr. 141.

Rothschedl, E. and Grössmann, N. (2023): Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Update July 2024. Fact Sheet Nr. 142.

Rothschedl, E. and Grössmann, N. (2023): Tislelizumab (Tevimbra®) as monotherapy for the treatment of unresectable, locally advanced, or metastatic oesophageal squamous cell carcinoma (OSCC). Update February 2024. Fact Sheet Nr. 143.

Rothschedl, E. and Grössmann, N. (2023): Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease. Update July/August 2023. Fact Sheet Nr. 144.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Update July/August 2023. Fact Sheet Nr. 145.

Rothschedl, E. and Grössmann, N. (2023): Brentuximab vedotin (Adcetris®) in combination with doxorubicin, vinblastine and dacarbazine for previously untreated CD30+ Stage III or IV Hodgkin lymphoma. Update February 2024. Fact Sheet Nr. 146.

Rothschedl, E. and Grössmann, N. (2023): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation. Update April 2024. Fact Sheet Nr. 147.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of non-small cell lung carcinoma (NSCLC). Update April 2024. Fact Sheet Nr. 148.

Rothschedl, E. and Grössmann, N. (2023): Quizartinib (Vanflyta®) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by single-agent maintenance therapy for patients with newly diagnosed acute myeloid leukaemia (AML). Update February 2024. Fact Sheet Nr. 150.

Rothschedl, E. and Grössmann, N. (2023): Melphalan flufenamide (Pepaxti®) in combination with dexamethasone for the treatment of multiple myeloma (MM). Fact Sheet Nr. 149.

Rothschedl, E. and Grössmann, N. (2023): Zanubrutinib (Brukinsa®) with obinutuzumab for the treatment of refractory or relapsed follicular lymphoma (FL). Fact Sheet Nr. 151.

Rothschedl, E. and Grössmann, N. (2023): Elranatamab (Elrexfio®) as monotherapy for the treatment of relapsed and refractory multiple myeloma (MM). Fact Sheet Nr. 152.

Rothschedl, E. and Grössmann, N. (2023): Durvalumab (Imfinzi®) as monotherapy for the first line treatment of advanced or unresectable hepatocellular carcinoma (HCC). Fact Sheet Nr. 153.

Rothschedl, E. and Grössmann, N. (2023): Dostarlimab (Jemperli®) with carboplatin and paclitaxel for the treatment of mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) primary advanced or recurrent endometrial cancer (EC). Fact Sheet Nr. 154.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. Fact Sheet Nr. 155.

Rothschedl, E. and Grössmann, N. (2023): Rucaparib (Rubraca®) as monotherapy for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. Fact Sheet Nr. 156.

Rothschedl, E. and Grössmann, N. (2023): Avapritinib (Ayvakyt®) for the treatment of indolent systemic mastocytosis (ISM). Fact Sheet Nr. 157.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma (BTC). Fact Sheet Nr. 158.

Rothschedl, E. and Grössmann, N. (2023): Adagrasib (Krazati®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 159.

Rothschedl, E. and Grössmann, N. (2023): Momelotinib (Omjjara®) for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (PMF), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. Fact Sheet Nr. 160.

Rothschedl, E. and Grössmann, N. (2023): Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update September 2024. Fact Sheet Nr. 161.

Rothschedl, E. and Grössmann, N. (2024): Idecabtagene vicleucel (Abecma®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies. Update September 2024. Fact Sheet Nr. 162.

Rothschedl, E. and Grössmann, N. (2024): Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer. Update September 2024. Fact Sheet Nr. 163.

Rothschedl, E. and Grössmann, N. (2024): Tislelizumab (Tizveni®) in monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Fact Sheet Nr. 164.

Rothschedl, E. and Grössmann, N. (2024): Retifanlimab (Zynyz®) as monotherapy for the first line treatment of patients with metastatic or recurrent locally advanced Merkel cell carcinoma. Fact Sheet Nr. 165.

Rothschedl, E. and Grössmann, N. (2024): Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM). Fact Sheet Nr. 166.

Rothschedl, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) as pre- and post-operative treatment of resectable non small cell lung carcinoma (NSCLC). Fact Sheet Nr. 167.

Rothschedl, E. and Grössmann, N. (2024): Irinotecan hydrochloride trihydrate (Onivyde® pegylated liposomal) in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Fact Sheet Nr. 168.

Rothschedl, E. and Grössmann, N. (2024): Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours. Fact Sheet Nr. 169.

Rothschedl, E. and Grössmann, N. (2024): Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC). Fact Sheet Nr. 170.

Rothschedl, E. and Grössmann, N. (2024): Fruquintinib (Fruzaqla®) as monotherapy for the treatment of metastatic colorectal cancer (mCRC). Fact Sheet Nr. 171.

Rothschedl, E. and Grössmann, N. (2024): Capivasertib (Truqap®) with fulvestrant for the treatment ER-positive, HER2‑negative locally advanced or metastatic breast cancer. Fact Sheet Nr. 172.

Rothschedl, E. and Grössmann, N. (2024): Alectinib (Alecensa®) as adjuvant treatment following complete tumour resection for adult patients with ALK‑positive non‑small cell lung cancer (NSCLC). Fact Sheet Nr. 173.

Rothschedl, E. and Grössmann, N. (2024): Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. Fact Sheet Nr. 174.

Rothschedl, E. and Grössmann, N. (2024): Entrectinib (Rozlytrek®) as monotherapy for the treatment of solid tumours with a NTRK gene fusion. Fact Sheet Nr. 175.

Rothschedl, E. and Grössmann, N. (2024): Amivantamab (Rybrevant®) with carboplatin and pemetrexed for the first‑line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations. Fact Sheet Nr. 176.

Rothschedl, E. and Grössmann, N. (2024): Sugemalimab (Cejemly®) with platinum-based chemotherapy for the first‑line treatment of metastatic non‑small‑cell lung cancer (NSCLC). Fact Sheet Nr. 177.

Rothschedl, E. and Grössmann, N. (2024): Osimertinib (Tagrisso®) with pemetrexed and platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 178.

Rothschedl, E. and Grössmann, N. (2024): Tislelizumab (Tevimbra®) monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Fact Sheet Nr. 179.

Rothschedl, E. and Grössmann, N. (2024): Erdafitinib (Balversa®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC). Fact Sheet Nr. 180.

Rothschedl, E. and Grössmann, N. (2024): Odronextamab (Ordspono®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuse large B‑cell lymphoma (r/r DLBCL). Fact Sheet Nr. 181.

Rothschedl, E. and Grössmann, N. (2024): Durvalumab (Imfinzi®) in combination with carboplatin and paclitaxel for the first-line treatment of primary advanced or recurrent endometrial cancer (EC), followed by maintenance treatment durvalumab (Imfinzi®) as monotherapy in EC that is mismatch repair deficient (dMMR) or in combination with olaparib (Lynparza®) in EC that is mismatch repair proficient (pMMR). Fact Sheet Nr. 182.

Rothschedl, E. and Grössmann, N. (2024): Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL). Fact Sheet Nr. 183.

Rothschedl, E. and Grössmann, N. (2024): Toripalimab (Loqtorzi®) in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC). Fact Sheet Nr. 184.

Rothschedl, E. and Grössmann, N. (2024): Toripalimab (Loqtorzi®) with cisplatin and paclitaxel for the first-line treatment of unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC). Fact Sheet Nr. 185.

Rothschedl, E. and Grössmann, N. (2024): Zolbetuximab (Vyloy®) with chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2‑negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Fact Sheet Nr. 186.

Rothschedl, E. and Grössmann, N. (2024): Encorafenib (Braftovi®) in combination with binimetinib (Mektovi®) for the treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 187.

Rothschedl, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) with enfortumab vedotin (Padcev®) for the first-line treatment of unresectable or metastatic urothelial carcinoma. Fact Sheet Nr. 188.

Rothschedl, E. and Grössmann, N. (2024): Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 189.

Rothschedl, E. and Grössmann, N. : Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of advanced NSCLC. Fact Sheet Nr. 190.

Rothschedl, E. and Grössmann, N. (2024): Serplulimab (Hetronifly®) with carboplatin and etoposide for the first‑line treatment of extensive‑stage small cell lung cancer (ES-SCLC). Fact Sheet Nr. 192.

Rothschedl, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) with chemoradiotherapy (CRT) for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer. Fact Sheet Nr. 194.

Rothschedl, E. and Malikova, E. and Grössmann, N. (2024): Mirvetuximab soravtansine (Elahere®) for the treatment of adults with folate receptor-alpha (FRα) positive epithelial ovarian, fallopian tube and primary peritoneal cancer. Fact Sheet Nr. 193.

Rothschedl, E and Malikova, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) for the treatment of adults with endometrial carcinoma. Fact Sheet Nr. 195.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 35th Prioritisation – 2nd quarter 2018. HSO: 35th Prioritisation.

Stanak, M. and Grössmann, N. and Strohmaier, C. (2019): 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer . Decision Support Document 118.

Grössmann, N. (2016): Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM). DSD: Horizon Scanning in Oncology 63.

Wolf, S. and Grössmann, N. (2017): Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer. DSD: Horizon Scanning in Oncology 65.

Grössmann, N. and Wolf, S. (2017): Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy. DSD: Horizon Scanning in Oncology 66.

Wild, C. and Grössmann, N. (2019): FoundationOne®CDx: genetic profiling of solid tumours. Rapid Assessment 014.

Grössmann, N. (2017): Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC). DSD: Horizon Scanning in Oncology 72.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 33rd Prioritisation – 4th quarter 2017. HSO: 33rd Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 39th Prioritisation – 2nd quarter 2019 . HSO: 39th Prioritisation.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 30th Prioritisation – 1st quarter 2017. HSO: 30th Prioritisation.

Grössmann, N. and Wild, C. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 25th Prioritisation – 4th quarter 2015. HSO: 25th Prioritisation.

Grössmann, N. (2020): Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions. Update July 2020. Oncology Fact Sheet Nr. 1.

Grössmann, N. (2020): Rituximab (MabThera®) for the treatment of paediatric patients with previously untreated advanced stage CD20 positive DLBCL, BL, BAL, or BLL. Oncology Fact Sheet Nr. 3.

Grössmann, N. and Wolf, S. and Rothschedl, E. (2019): Horizon Scanning in Oncology 38th Prioritisation – 1st quarter 2019. HSO: 38th Prioritisation.

Grössmann, N. (2016): Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy. DSD: Horizon Scanning in Oncology 59.

Grössmann, N. (2020): Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC). Update July 2020. Oncology Fact Sheet Nr. 2.

Grössmann, N. (2020): Brigatinib (Alunbrig®) in ALK-positive non–small-cell lung cancer (NSCLC). Update July 2020. Oncology Fact Sheet Nr. 4.

Grössmann, N. (2017): Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC). DSD: Horizon Scanning in Oncology 70.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 41st Prioritisation – 4th quarter 2019. HSO: 41st Prioritisation.

Grössmann, N. (2020): Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM). Update July 2020. Oncology Fact Sheet Nr. 6.

Rosian, K. and Fischer, S. and Grössmann, N. (2018): Inhalation sedation with laughing gas (N2O) in dentistry – organisational and professional aspects and a systematic review of efficacy and safety. HTA-Projektbericht 105.

Grössmann, N. (2016): Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion. DSD: Horizon Scanning in Oncology 62.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 37th Prioritization – 4th quarter 2018. HSO: 37th Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 40th Prioritisation – 3rd quarter 2019. HSO: 40th Prioritisation.

Robausch, M. and Grössmann, N. (2020): Health Services Research in Oncology. Part I: End-of-Life Care . HTA-Projektbericht 127.

Grössmann, N. (2020): Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL). Update July 2020. Oncology Fact Sheet Nr. 5.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 32nd Prioritisation – 3rd quarter 2017. HSO: 32nd Prioritisation.

Grössmann, N. and Wolf, S. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 29th Prioritisation – 4th quarter 2016.. HSO: 29th Prioritisation.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 31st Prioritisation – 2nd quarter 2017 . HSO: 31st Prioritisation.

Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 27th Prioritisation – 2nd quarter 2016 . HSO: 27th Prioritisation.

Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 28th Prioritisation – 3rd quarter 2016. HSO: 28th Prioritisation.

Fuchs, S. and Grössmann, N. and Eckhardt, H. and Busse, R. and Wild, C. (2018): PET/PET-CT Evidence for need based planning in Germany and Austria. HTA-Projektbericht 77/ Update 2018.

Grössmann, N. (2017): Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC). DSD: Horizon Scanning in Oncology 75.

Grössmann, N. and Wild, C. and Mayer, J. (2016): Drugs in Oncology: an overview of benefit and refund practices in Europe. Rapid Assessment 008.

Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 26th Prioritisation – 1st quarter 2016. HSO: 26th Prioritisation.

Grössmann, N. and Baumann, M. (2016): Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL). DSD: Horizon Scanning in Oncology 57.

Baumann, M. and Grössmann, N. (2016): Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 58.

Grössmann, N. (2016): Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL). DSD: Horizon Scanning in Oncology 60.

Grössmann, N. and Wolf, S. (2018): Horizon Scanning in Oncology 34th Prioritisation – 1st quarter 2018. HSO: 34th Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 36th Prioritisation – 3rd quarter 2018. HSO: 36th Prioritisation.